Stuttgart’s Medicaid spending on non-oral drug administration jumps 31.7% in 2024

In Stuttgart, Medicaid providers reported $3,879 in claims for Drugs Administered Other than Oral Method services in 2024, as shown in the U.S. Department of Health and Human Services Medicaid Provider Spending database. This total marks a 31.7% rise from 2023, when claims for the same services reached $2,946.

Medicaid, a major public health insurance initiative, is operated by states and jointly funded by federal and state governments. It covers seniors, children, people with disabilities and low-income individuals and families, making it a key component of the U.S. health care system.

Because Medicaid is funded through taxpayer dollars, fluctuations in city-level billing show how public health spending is distributed within the community.

The “Drugs Administered Other than Oral Method” category includes a range of Medicaid-reimbursed services, determined by standardized groupings of HCPCS and CPT billing codes. To maintain accuracy and avoid duplicate counts, billing codes were assigned to one service category each based on code prefixes and number ranges during this analysis, supporting year-to-year comparisons and rankings.

Despite increased spending in different service areas, Drugs Administered Other than Oral Method finished 10th among all Medicaid categories by total payments in Stuttgart for 2024.

Statewide, this category placed 14th in Arkansas by Medicaid payment totals in 2024.

From 2019 through 2024, Medicaid payments for Drugs Administered Other than Oral Method in Stuttgart increased $22,574, a gain of 85.3%. This upward trend featured pronounced year-over-year surges, with notable increases in both 2023 and 2022.

Spending for Drugs Administered Other than Oral Method was distributed citywide but was heavily concentrated in just a few ZIP codes during 2024. ZIP code 72160 accounted for $3,878 in Medicaid payments for this category, representing 100% of Stuttgart’s spending in this area for the year.

A small number of billing codes captured most of the Medicaid spending within the Drugs Administered Other than Oral Method grouping.

For comparison, while Medicaid payments tied to the Drugs Administered Other than Oral Method category in Stuttgart rose 31.7% from 2023 to 2024, overall Medicaid payments for all claim categories in the city increased by 28.8% across the same period.

According to the Centers for Medicare & Medicaid Services, combined federal and state Medicaid spending was approximately $871.7 billion in fiscal year 2023. That accounted for about 18% of national health expenditures, up considerably from roughly $613.5 billion in 2019 before the COVID-19 pandemic.

This increase represents nearly a 40% jump within just a few years, driven primarily by expanded enrollment and greater service use during and after the pandemic era.

Recent federal budget measures from the Trump administration featured notable recommendations to reduce Medicaid funding and revise the program’s structure. The “One Big Beautiful Bill Act,” enacted in 2025, is expected to decrease federal Medicaid outlays by over $1 trillion in the coming decade. The law also introduces work requirements and expanded cost-sharing, which may limit coverage and decrease funding for some recipients, shifting more financial responsibility to states and slowing federal spending growth while the program continues to serve millions nationwide.

Note: HCPCS codes are shown for context within the category. Category totals and rankings in this article are based on standardized service groupings rather than individual billing codes.

Information in this article was obtained from the U.S. Department of Health and Human Services Medicaid Provider Spending database. The source data can be found here.